Potential Interactions between Exercise and Drug Therapy

被引:0
|
作者
Thomas L. Lenz
Nancy J. Lenz
Michele A. Faulkner
机构
[1] Creighton University Medical Center,Department of Pharmacy Practice, School of Pharmacy and Health Professions
[2] Madonna Rehabilitation Hospital,Physical Therapy Department
[3] Creighton University Medical Center,School of Pharmacy and Health Professions
来源
Sports Medicine | 2004年 / 34卷
关键词
Warfarin; Propranolol; Digoxin; Theophylline; Atenolol;
D O I
暂无
中图分类号
学科分类号
摘要
Certain physiological changes caused by aerobic exercise can alter the pharmacokinetics of some drugs. A systematic review of the pharmacokinetic changes that can affect drugs as a result of aerobic exercise is provided. Eleven commonly used drugs are reviewed for their potential interaction with exercising patients. Serum concentrations of two β-blocking agents, atenolol and propranolol, and one antibiotic, doxycycline, have shown to increase as a result of exercise. No pharmacokinetic changes have been found in exercising patients taking Carvedilol or verapamil. Patients who exercise after taking digoxin experience a decreased digoxin serum concentration with an increased skeletal muscle concentration. The clearance of theophylline has been shown to decrease resulting in an increase in plasma half-life during exercise. The risk of hypoglycaemia may increase when patients with diabetes mellitus inject insulin into a muscle just prior to exercising that muscle. Increasing physical activity in patients taking warfarin has been shown to decrease the international normalised ratio. Much is still unknown regarding the interactions that exist between exercise and drug therapy. More studies need to be completed in this area before definite conclusions are made and clinical relevance can be established. Clinicians should be aware that the potential for such interactions exists, especially for drugs with a narrow therapeutic range and in patients who participate in extreme sporting activities.
引用
收藏
页码:293 / 306
页数:13
相关论文
共 50 条
  • [21] Potential Drug Interactions Between Cannabinoids and Its Derivatives and Oral Anticoagulants
    Paduch, McKenzie
    Thomason, Angela R.
    HOSPITAL PHARMACY, 2022, 57 (01) : 188 - 192
  • [22] Potential drug interactions with cyclosporine
    Katz, HI
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 1997, 36 : 18 - 24
  • [23] Interactions between insulin and exercise
    Richter, Erik A.
    Sylow, Lykke
    Hargreaves, Mark
    BIOCHEMICAL JOURNAL, 2021, 478 (21) : 3827 - 3846
  • [24] Potential drug interactions with melatonin
    Papagiannidou, Eleni
    Skene, Debra J.
    Ioannides, Costas
    PHYSIOLOGY & BEHAVIOR, 2014, 131 : 17 - 24
  • [25] Terbinafine and potential drug interactions
    Kaplan, DL
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (05) : 882 - 882
  • [26] DRUG UTILIZATION AND POTENTIAL DRUG-DRUG INTERACTIONS
    LAVENTURIER, MF
    TALLEY, RB
    HEFNER, DL
    KENNARD, LH
    JOURNAL OF THE AMERICAN PHARMACEUTICAL ASSOCIATION, 1976, 16 (02): : 77 - 81
  • [27] THE POTENTIAL FOR DRUG-INTERACTIONS
    KARAS, S
    ANNALS OF EMERGENCY MEDICINE, 1981, 10 (12) : 627 - 630
  • [28] Drug-Gene Interactions between Genetic Polymorphisms and Antihypertensive Therapy
    Hedi Schelleman
    Bruno H. Ch. Stricker
    Anthonius de Boer
    Abraham A. Kroon
    Monique W. M. Verschuren
    Cornelia M. van Duijn
    Bruce M. Psaty
    Olaf H. Klungel
    Drugs, 2004, 64 : 1801 - 1816
  • [29] Drug-gene interactions between genetic polymorphisms and antihypertensive therapy
    Schelleman, H
    Stricker, BHC
    de Boer, A
    Kroon, AA
    Verschuren, MWM
    van Duijn, CM
    Psaty, BM
    Klungel, OH
    DRUGS, 2004, 64 (16) : 1801 - 1816
  • [30] Potential Drug Interactions Forgotten
    Regenthal, Ralf
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2019, 116 (05): : 71 - 72